Corvex, Inc. (MOVE) Q4 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

including a $3 million strategic seed investment from a tier one multi-billion dollar global medical device company. This is a pivotal moment in our company's journey. We're thrilled to partner with this leader in healthcare and look forward to potential future collaborations. As we highlighted in our press release earlier this week, this strategic investor is keenly interested in the EV ring and our proprietary millimeter wave radio frequency technology And this event underscores the vast potential of our innovative approach to delivering medical grade data to both consumers and enterprises. We're also fortunate to have had the broad participation in the private placement from Havana Health's management team and board of directors, totaling more than $3.6 million. Now, with the new financing, we are set up to scale commercial production proceed further along the regulatory pathway and pursue multiple market opportunities that should deliver shareholder value. Our goal is to deliver both the consumer and FDA cleared wearable that combines accessibility, personalization, and style with the recognized capabilities of a medical device. Our highest priorities are as follows. One, to achieve our first FDA clearance for pulse rate and blood oxygen monitoring, which sets the stage for our brand expansion to EV Med. Two, on the heels of this clearance to bring key B2B opportunities to fruition. And three, to accelerate our clinical trials for cupless blood pressure and noninvasive glucose monitoring, establishing the foundation to develop additional commercial products leveraging our proprietary technology. Movano Health is using EV to set new standards for the possibilities of what wearable health technology can do. We plan to serve consumers through both D2C and B2B channe...